Zogenix Submits New Drug Application to U.S. Food & Drug Administration and Marketing Authorization Application to European Medicines Agency for FINTEPLA® for the Treatment of Dravet Syndrome
February 06, 2019 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Feb. 06, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced it has completed its rolling...
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
February 01, 2019 16:43 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Feb. 01, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
January 02, 2019 16:05 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
December 03, 2018 16:05 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix Announces Positive Phase 3 Trial Results on the Efficacy and Safety of FINTEPLA® (ZX008) in Dravet Syndrome
December 03, 2018 09:00 ET
|
Zogenix, Inc.
Positive Data from Second Pivotal Phase 3 Trial (Study 1504) Consistent with Results of First Phase 3 Trial in Showing Highly Significant Convulsive Seizure Reduction for FINTEPLA versus Placebo ...
Zogenix Presents Positive Findings on the Impact of Treatment with FINTEPLA® (ZX008) on Everyday Executive Function in Patients with Dravet Syndrome
December 02, 2018 09:00 ET
|
Zogenix, Inc.
Data Presented During Late-Breaker Session at 72nd American Epilepsy Society Annual Meeting Additional New Analyses Underscore Psychosocial Burden on Family EMERYVILLE, Calif., Dec. 02, 2018 ...
Zogenix to Host Investor Update Lunch on FINTEPLA® at the American Epilepsy Society 2018 Annual Meeting
November 29, 2018 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Nov. 29, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare diseases, today announced that it will...
Zogenix to Participate in the Global Mizuho Investor Conference 2018
November 27, 2018 08:00 ET
|
Zogenix, Inc.
EMERYVILLE, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
Zogenix to Announce New Data at 72nd American Epilepsy Society Annual Meeting
November 26, 2018 08:00 ET
|
Zogenix, Inc.
Full Results from Second Pivotal Phase 3 Trial of FINTEPLA® (ZX008) in Dravet Syndrome (Study 1504) New Long-Term Efficacy and Safety Data from Open-Label Extension Trial (Study 1503) Studies on the...
Zogenix Provides Corporate Update and Reports Third Quarter Financial Results
November 08, 2018 16:01 ET
|
Zogenix, Inc.
Reported positive top-line results from second pivotal Phase 3 trial of FINTEPLA® (ZX008) in patients with Dravet syndrome, Study 1504Initiated rolling NDA submission to FDA for FINTEPLAContinued to...